MedPath

The Effect of Omega 3 Supplementation on Postoperative Delirium in Elderly Patients Undergoing Major Cardiac Surgery

Phase 2
Not yet recruiting
Conditions
Postoperative Delirium
Interventions
Registration Number
NCT06434948
Lead Sponsor
University of Missouri-Columbia
Brief Summary

The purpose of this study is to determine whether giving omega-3 fatty acids prior to and after cardiac bypass surgeries decreases the incidence of postoperative delirium in patients aged 65 and over.

Detailed Description

Patients aged 65 years and over requiring elective cardiac bypass surgeries will receive either 0, 2, or 4 grams of omega-3 ethyl esters before their surgery and for 3 days postoperatively to determine whether there is an affect on the incidence of postoperative delirium. All patients will receive hospital standard of care therapy for their surgery and hospital stay.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
90
Inclusion Criteria
  • Age ≥ 65 years
  • American Society of Anesthesiologists (ASA) Class Physical Status I-IV
Exclusion Criteria
  • Inability to obtain written informed consent.
  • Inability to take study drug due to intubation or other reason.
  • Delirium present at screening.
  • Known hypersensitivity (e.g. anaphylactic reaction) to omega-3 ethyl esters or any of its components
  • Allergy to fish or shellfish
  • Currently taking warfarin (Coumadin), apixaban (Eliquis), dabigatran (Pradaxa), edoxaban (Savaysa/Lixiana), rivaroxaban (Xarelto), or other anticoagulant drugs.
  • Currently taking omega-3, omega-6, vitamin E, or fish oil supplements.
  • Significant renal disease with a serum creatinine ≥ 2 mg/dL.
  • Significant liver disease with alanine aminotransferase (ALT) levels 1.5 times the normal range of 6-45 units/liter and aspartate transferase (AST) levels 1.5 times the normal range of 10-42 units/liter.
  • History or diagnosis of diabetes.
  • History or diagnosis of neurodegenerative disease such as Parkinson's, Alzheimer's, or dementia.
  • History or diagnosis of bleeding disorder.
  • History or diagnosis of metabolic syndrome or disorder.
  • History or diagnosis of thyroid problems such as hyperthyroidism or hypothyroidism.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Omega-3 Ethyl Esters 4 gOmega-3 Ethyl Esters 4 gPatients will be given 4 grams of omega-3 ethyl esters orally before surgery and for 3 days postoperatively.
Omega-3 Ethyl Esters 2 gOmega-3 Ethyl Esters 2 gPatients will be given 2 grams of omega-3 ethyl esters orally before surgery and for 3 days postoperatively.
Primary Outcome Measures
NameTimeMethod
Presence of Postoperative DeliriumFrom the date of surgery until the patient is discharged, up to 30 days.

Number of patients that experienced postoperative delirium during the study.

Secondary Outcome Measures
NameTimeMethod
Postoperative Delirium SymptomsFrom the date of surgery until the patient is discharged, up to 30 days.

Presence of any postoperative delirium symptoms during patient's hospital stay.

Length of StayFrom the date of surgery until the patient is discharged, up to 30 days.

Number of days patient stayed in hospital from the time of admission to discharge.

Type of Anesthesia UsedDuring surgery, up to 24 hours

Number of patients administered anesthesia using mainly propofol or sevoflurane.

Amount of Pain Medication Given PostoperativelyFrom the date of surgery until the patient is discharged, up to 30 days.

Average morphine milligram equivalents given to patients postoperatively until their discharge from the hospital.

Trial Locations

Locations (1)

University Hospital

🇺🇸

Columbia, Missouri, United States

© Copyright 2025. All Rights Reserved by MedPath